
Opinion|Videos|November 18, 2015
Dr. Andre Goy on Future Treatments for Patients With Diffuse Large B-Cell Lymphoma
Author(s)Andre Goy, MD
Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Advertisement
Andre Goy, MD, MS, chief, John Theurer Cancer Center Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Goy says that some of the upcoming novel agents showing promise are bortezomib, both as a single agent and in conjunction with R-CHOP chemotherapy, as well as ibrutinib. Both ibrutinib and bortezomib showed great promise in phase II clinical trials and will be going on to phase III trials to determine their viability as treatments.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5








































